Search

Scabies is a human ectoparasitosis caused by Sarcoptes scabei var. hominis. World-wide around 300 million patients are affected. Infants and children have the highest incidence rates. Poverty and overcrowding are social factors contributing to a higher risk of transmission and treatment failure. The leading symptom of the infestation is itch. Complications are bacterial infections that are responsible for mortality. Diagnosis is clinical. Non-invasive imaging technologies like dermoscopy can be used. Polymerase chain reaction (PCR) is less sensitive and specific than microscopy of skin scrapings. Treatment of choice is topical permethrin 5%. Ivermectin is the only oral drug FDA-approved for scabies. It should be used in cases non-responsive to topical therapy and in case of high number of infested patients in addition to topical therapy. Pseudo-resistance to treatment is not uncommon. New drugs are on the horizon. What is Known: • Pruritus is the leading symptom causing sleep disturbances and scratching with the risk of secondary bacterial infections. • Treatment failure is related to inappropriate application of topical drugs and asymptomatic family members. What is New: • COVID-19 pandemic and migration are contributing to an increased incidence of scabies. • New compounds to treat scabies are on the horizon. [ABSTRACT FROM AUTHOR]

This correction notice is for an article titled "Scabies in infants and children - a narrative review" published in the European Journal of Pediatrics. The correction states that the co-author, Anca E. Chiriac, was inadvertently omitted during the publication process and has now been added as the fourth author. The original article can be found online at the provided link. The publisher, Springer Nature, remains neutral regarding jurisdictional claims and institutional affiliations. The correction notice is reported by the authors: Anca Chiriac, Adriana Diaconeasa, Raluca Miulescu, Anca E. Chiriac, and Uwe Wollina. [Extracted from the article]